BioCentury | May 6, 2020
Management Tracks

Abrams resigns as Editas CMO; plus Immunocore, Spruce, Frazier, Horama and more

...manufacturing. Gharib was CFO of Stemedica Cell Technologies Inc.; Reddy was head of CMC at Landos Biopharma Inc....
BioCentury | Dec 10, 2019
Finance

Perceptive launches $210M early-stage fund tied to Garabedian’s accelerator Xontogeny

...this week, but it has already invested in two therapeutics companies: Quellis Biosciences Inc. and Landos Biopharma Inc....
...Quellis; Garabedian and PXV Partner Fred Callori hold board seats. PXV contributed $11.6 million to Landos’...
...first-in-class oral small molecule targets lanC like 2 (LANCL2) (see “$60M B Round to Propel Landos...
BioCentury | Oct 16, 2019
Financial News

Oct. 15 Financial Quick Takes: Phathom, Galera, J&J earnings, RTW Investments, Azitra, MaveriX

...Exchange. The firm has invested in Beta Bionics Inc., Frequency Therapeutics Inc. (NASDAQ:FREQ), Immunocore Ltd., Landos Biopharma Inc....
BioCentury | Aug 14, 2019
Financial News

$60M B round to propel Landos through Phase II IBD trials

...BT-11. Chairman, President and CEO Josep Bassaganya-Riera told BioCentury he expects the funding to last Landos Biopharma Inc....
...investor Perceptive Advisors, via the Perceptive Xontogeny Venture Fund and Perceptive Life Sciences Fund, co-led Landos'...
...is chairman and CEO of the accelerator and a Landos board member (see "Clear for Landos"...
BioCentury | Apr 20, 2018
Emerging Company Profile

Clear for Landos

...inhibition can lead to significant side effects including infection and cancer, said CEO Josep Bassaganya-Riera. Landos...
...to exert a broader effect because it activates multiple pathways that lead to decreased inflammation. Landos...
...According to BCIQ, there are no NLRX1 agonists in the clinic for IBD. Bassaganya-Riera said Landos...
BioCentury | Sep 22, 2017
Financial News

Landos spins out of Xontogeny accelerator

...On Sept. 21, Landos Biopharma Inc. (Blacksburg, Va.) spun out of life sciences accelerator Xontogeny LLC (Boston, Mass...
...enable Landos to complete Phase I testing of BT-11 for Crohn's disease by early 2019. Landos...
...the number of companies in the accelerator. Garabedian joined Landos’ board. Landos Biopharma Inc. , Blacksburg, Va. Alicia Parker BT-11 Landos Biopharma Inc. Xontogeny...
BioCentury | Sep 21, 2017
Financial News

Landos spins out of Xontogeny accelerator

...enable Landos to complete Phase I testing of BT-11 for Crohn's disease by early 2019. Landos...
...the number of companies in the accelerator. Garabedian joined Landos’ board. Virginia Li Xontogeny LLC LanC like 2 (LANCL2) BT-11 Landos Biopharma Inc....
Items per page:
1 - 7 of 7
BioCentury | May 6, 2020
Management Tracks

Abrams resigns as Editas CMO; plus Immunocore, Spruce, Frazier, Horama and more

...manufacturing. Gharib was CFO of Stemedica Cell Technologies Inc.; Reddy was head of CMC at Landos Biopharma Inc....
BioCentury | Dec 10, 2019
Finance

Perceptive launches $210M early-stage fund tied to Garabedian’s accelerator Xontogeny

...this week, but it has already invested in two therapeutics companies: Quellis Biosciences Inc. and Landos Biopharma Inc....
...Quellis; Garabedian and PXV Partner Fred Callori hold board seats. PXV contributed $11.6 million to Landos’...
...first-in-class oral small molecule targets lanC like 2 (LANCL2) (see “$60M B Round to Propel Landos...
BioCentury | Oct 16, 2019
Financial News

Oct. 15 Financial Quick Takes: Phathom, Galera, J&J earnings, RTW Investments, Azitra, MaveriX

...Exchange. The firm has invested in Beta Bionics Inc., Frequency Therapeutics Inc. (NASDAQ:FREQ), Immunocore Ltd., Landos Biopharma Inc....
BioCentury | Aug 14, 2019
Financial News

$60M B round to propel Landos through Phase II IBD trials

...BT-11. Chairman, President and CEO Josep Bassaganya-Riera told BioCentury he expects the funding to last Landos Biopharma Inc....
...investor Perceptive Advisors, via the Perceptive Xontogeny Venture Fund and Perceptive Life Sciences Fund, co-led Landos'...
...is chairman and CEO of the accelerator and a Landos board member (see "Clear for Landos"...
BioCentury | Apr 20, 2018
Emerging Company Profile

Clear for Landos

...inhibition can lead to significant side effects including infection and cancer, said CEO Josep Bassaganya-Riera. Landos...
...to exert a broader effect because it activates multiple pathways that lead to decreased inflammation. Landos...
...According to BCIQ, there are no NLRX1 agonists in the clinic for IBD. Bassaganya-Riera said Landos...
BioCentury | Sep 22, 2017
Financial News

Landos spins out of Xontogeny accelerator

...On Sept. 21, Landos Biopharma Inc. (Blacksburg, Va.) spun out of life sciences accelerator Xontogeny LLC (Boston, Mass...
...enable Landos to complete Phase I testing of BT-11 for Crohn's disease by early 2019. Landos...
...the number of companies in the accelerator. Garabedian joined Landos’ board. Landos Biopharma Inc. , Blacksburg, Va. Alicia Parker BT-11 Landos Biopharma Inc. Xontogeny...
BioCentury | Sep 21, 2017
Financial News

Landos spins out of Xontogeny accelerator

...enable Landos to complete Phase I testing of BT-11 for Crohn's disease by early 2019. Landos...
...the number of companies in the accelerator. Garabedian joined Landos’ board. Virginia Li Xontogeny LLC LanC like 2 (LANCL2) BT-11 Landos Biopharma Inc....
Items per page:
1 - 7 of 7